Woodland Research Northwest, Llc
- Type
- Non-covered entity
- Where
- Rogers, AR
- Received
- $1,651,491 in 37 records, 2019 to 2025 ($0 general, $1,651,491 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 4 | $25,869 |
| 2021 | Research payment | 9 | $1,477,005 |
| 2020 | Research payment | 20 | $142,685 |
| 2019 | Research payment | 4 | $5,931 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 24 | $1,624,912 | 2019–2021 |
| E.R. Squibb & Sons, L.L.C. | 4 | $25,869 | 2025 |
| Alkermes, Inc. | 9 | $709 | 2019–2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 37 | $1,651,491 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-11-24 | E.R. Squibb & Sons, L.L.C. | $19,800 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with M | 2025 | |
| 2025-10-27 | E.R. Squibb & Sons, L.L.C. | $1,439 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with M | 2025 | |
| 2025-07-28 | E.R. Squibb & Sons, L.L.C. | $1,717 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treat | 2025 | |
| 2025-05-14 | E.R. Squibb & Sons, L.L.C. | $2,912 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treat | 2025 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $216,986 | Research payment | In-kind items and services | Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $67,892 | Research payment | In-kind items and services | Drug, NEUROSCIENCE | A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Parti | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,677 | Research payment | In-kind items and services | Drug, NEUROSCIENCE | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzhe | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $993 | Research payment | In-kind items and services | Drug, NEUROSCIENCE | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzhe | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $475 | Research payment | In-kind items and services | Drug, NEUROSCIENCE | A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Parti | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $203 | Research payment | In-kind items and services | Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2021 |
| 2021-11-17 | Merck Sharp & Dohme LLC | $836,122 | Research payment | Cash or cash equivalent | Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2021 |
| 2021-10-27 | Merck Sharp & Dohme LLC | $146,973 | Research payment | Cash or cash equivalent | Drug, NEUROSCIENCE | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzhe | 2021 |
| 2021-10-06 | Merck Sharp & Dohme LLC | $193,680 | Research payment | Cash or cash equivalent | Drug, NEUROSCIENCE | A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Parti | 2021 |
| 2020-12-16 | Merck Sharp & Dohme LLC | $749 | Research payment | In-kind items and services | MK-8189 Drug, NEUROSCIENCE | A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Parti | 2020 |
| 2020-11-30 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2020 |
| 2020-11-23 | Merck Sharp & Dohme LLC | $74 | Research payment | In-kind items and services | MK-8189 Drug, NEUROSCIENCE | A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Parti | 2020 |
| 2020-11-18 | Merck Sharp & Dohme LLC | $66,000 | Research payment | Cash or cash equivalent | MK-8189 Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2020 |
| 2020-11-17 | Merck Sharp & Dohme LLC | $25 | Research payment | In-kind items and services | MK-8189 Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2020 |
| 2020-11-13 | Merck Sharp & Dohme LLC | $4,142 | Research payment | In-kind items and services | MK-8189 Drug, NEUROSCIENCE | A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Parti | 2020 |
| 2020-11-13 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | MK-8189 Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2020 |
| 2020-11-11 | Merck Sharp & Dohme LLC | $718 | Research payment | In-kind items and services | MK-8189 Drug, NEUROSCIENCE | A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Parti | 2020 |
| 2020-10-31 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $2,038 | Research payment | In-kind items and services | MK-8189 Drug, NEUROSCIENCE | A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Parti | 2020 |
| 2020-10-05 | Merck Sharp & Dohme LLC | $27 | Research payment | In-kind items and services | MK-8189 Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2020 |
| 2020-09-09 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | MK-8189 Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2020 |
| 2020-07-23 | Merck Sharp & Dohme LLC | $276 | Research payment | In-kind items and services | MK-8189 Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2020 |
| 2020-07-01 | Merck Sharp & Dohme LLC | $47,222 | Research payment | Cash or cash equivalent | MK-8189 Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2020 |
| 2020-07-01 | Merck Sharp & Dohme LLC | $11,500 | Research payment | Cash or cash equivalent | MK-8189 Drug, NEUROSCIENCE | A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titrat | 2020 |
| 2020-06-14 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2020 |
| 2020-05-15 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $8,400 | Research payment | Cash or cash equivalent | MK-1942 Drug, NEUROSCIENCE | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzhe | 2020 |
| 2020-02-14 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2020 |
| 2020-01-14 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2020 |
| 2019-10-31 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2019 |
| 2019-10-16 | Alkermes, Inc. | $68 | Research payment | In-kind items and services | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2019 |
| 2019-04-16 | Alkermes, Inc. | $45 | Research payment | In-kind items and services | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2019 |
| 2019-04-12 | Merck Sharp & Dohme LLC | $5,731 | Research payment | Cash or cash equivalent | MK-8189 Drug, NEUROSCIENCE | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 using Ris | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rogers, AR, county Benton County, AR, state Arkansas; placed by its city name.
| Measure | Place (city or town) Rogers, AR | County Benton County, AR | State Arkansas |
|---|---|---|---|
| Population B01003 | 72,981 | 303,632 | 3,049,391 |
| Population, 2020 census P1 | 69,908 | 284,333 | 3,011,524 |
| Median age B01002 | 34.3 | 35.9 | 38.5 |
| Under 18 B01001 | 26.3% | 25.4% | 23.1% |
| 65 and over B01001 | 12.0% | 13.8% | 17.6% |
| Households B11001 | 26,265 | 111,919 | 1,205,987 |
| Foreign born B05002 | 18.0% | 12.7% | 5.4% |
| Median household income B19013 | $86,728 | $93,506 | $60,773 |
| Median family income B19113 | $98,106 | $108,069 | $76,968 |
| Per capita income B19301 | $44,802 | $47,067 | $34,225 |
| Poverty rate B17001 | 10.5% | 7.6% | 16.0% |
| Unemployment rate B23025 | 2.5% | 3.1% | 4.9% |
| Civilian labor force B23025 | 38,807 | 156,921 | 1,411,269 |
| Mean commute (minutes) B08013 | 18.2 | 21.6 | 22.5 |
| Bachelor's degree or higher B15003 | 34.4% | 37.8% | 25.7% |
| Housing units B25001 | 28,579 | 122,703 | 1,394,673 |
| Owner-occupied B25003 | 57.2% | 67.0% | 66.4% |
| Renters B25003 | 42.8% | 33.0% | 33.6% |
| Median home value B25077 | $308,200 | $323,500 | $188,000 |
| Median gross rent B25064 | $1,270 | $1,277 | $947 |
| White, not Hispanic B03002 | 49.0% | 58.0% | 67.4% |
| Black B03002 | 1.0% | 1.8% | 14.6% |
| Hispanic or Latino B03002 | 33.9% | 18.5% | 9.0% |
| Asian B03002 | 2.7% | 4.6% | 1.6% |
| American Indian and Alaska Native B03002 | 0.2% | 0.6% | 0.3% |
Economy now FRED unemployment 3.9% in Sep 2026 (4.2% a year earlier); per capita personal income $61,697 in 2025, up 31% in five years (+5.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rogers, AR.
Comments